Peptide HSA FSA: Which Peptides Qualify and How to Pay Less in 2026

What IRS Section 213(d) Actually Says About Peptide Therapy

The IRS uses Section 213(d) of the Internal Revenue Code as the governing standard for every HSA and FSA reimbursement decision. That section covers expenses paid for the "diagnosis, cure, mitigation, treatment, or prevention of disease" and for "prescription drugs" specifically. General health and wellness purchases do not qualify, regardless of how strong the underlying science is.

For a peptide to clear this bar cleanly, it needs one of three things: FDA approval as a prescription drug, a pharmacist-dispensed compounded preparation written on a licensed physician's prescription for a recognized diagnostic code, or classification as a qualifying medical device (not applicable to injectable or topical peptides). IRS Publication 502 spells this out in plain language and is updated annually.

The practical result is a two-tier system. FDA-approved peptide drugs, including semaglutide, liraglutide, insulin analogs, and tesamorelin, are unambiguously HSA/FSA eligible because they satisfy the prescription drug definition. Off-label or research-grade peptides like BPC-157, TB-500, and GHK-Cu occupy a gray zone where eligibility depends almost entirely on whether a physician has written a documented prescription and whether your specific plan administrator accepts that documentation. Plan administrators are not required to follow the most permissive interpretation of 213(d); many apply strict FDA-approval filters automatically.

According to IRS Revenue Ruling 2003-102, nonprescription drugs purchased without a prescription do not qualify even if a physician recommends them. That ruling was partially modified by the CARES Act of 2020 for over-the-counter medications, but compounded peptides do not fall under the OTC drug category modified by CARES. They remain prescription-dependent for reimbursement purposes.

The HealthRX reimbursement decision framework for compounded peptides uses four checkpoints before advising patients to submit an HSA/FSA claim:

1. Is the peptide dispensed by an FDA-registered 503A or 503B compounding pharmacy?
2. Does the patient hold a current, dated prescription from a licensed MD, DO, NP, or PA listing a specific ICD-10 diagnosis code?
3. Has the patient confirmed in writing with their plan administrator (not assumed) that the compound will be accepted?
4. Is the receipt itemized to show the prescription number, dispenser NPI, and drug name?

If any checkpoint fails, the claim carries meaningful audit risk. Only proceed if all four are green.

BPC-157 Cost Per Month and What Drives the Price

BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide studied in animal models for gastric mucosal healing and tendon repair. Preclinical data published in the Journal of Physiology show accelerated Achilles tendon healing in rat models, but no Phase II or Phase III human clinical trials have been completed and published as of early 2025. The FDA has not approved BPC-157 for any indication, and in March 2022 the FDA's Center for Drug Evaluation and Research placed BPC-157 on the "Difficult to Compound" list, effectively prohibiting 503B outsourcing facilities from compounding it for office stock.

503A pharmacies (patient-specific prescription only) can still compound BPC-157 in some states, which is why it remains available through certain telehealth prescribers. Monthly cost at those pharmacies typically falls between $80 and $180 for a 5 mg injectable vial kit that covers approximately 30 days of a standard low-dose protocol (250 to 500 mcg subcutaneous daily). Oral capsule formulations are cheaper, around $50 to $100 per month, though oral bioavailability data in humans is essentially absent.

Pricing variation comes from four factors: the pharmacy's cost of raw active pharmaceutical ingredient (API), overhead for sterility testing (required for injectables), prescriber consultation fees bundled into telehealth subscriptions, and shipping to your state. Patients in states with restrictive compounding pharmacy regulations may pay a 20 to 30 percent premium for out-of-state shipping.

HSA/FSA eligibility for BPC-157: possible only at a 503A pharmacy with a valid prescription and prior written approval from your plan administrator. Do not assume approval. The FDA's compounding concerns make many plan administrators automatically deny BPC-157 claims.

TB-500 Cost Per Month and the Thymosin Beta-4 Distinction

TB-500 is the colloquial name for a synthetic fragment of thymosin beta-4 (Tβ4), specifically the actin-binding domain peptide Ac-SDKP. Thymosin beta-4 itself has been studied in wound healing. A Phase II trial (N=72) reported by RegeneRx Biopharmaceuticals tested Tβ4 ophthalmic solution for dry eye and found statistically significant improvements in corneal staining scores compared to vehicle (P<0.05) at 28 days. See the published abstract via PubMed. That trial used a specific ophthalmic formulation, not the injectable TB-500 sold through compounding pharmacies.

Injectable TB-500 as sold for performance and recovery purposes is not FDA-approved. Monthly cost ranges from $100 to $220 for a 5 mg to 10 mg kit, depending on whether a patient follows a loading protocol (typically 4 to 8 mg per week for the first two weeks) or a maintenance protocol (2 to 6 mg per week thereafter). A loading month costs more, often reaching $200 or above at standard 503A pharmacy pricing.

Insurance will not cover TB-500 under any 2026 formulary HealthRX has reviewed. HSA/FSA eligibility follows the same logic as BPC-157: prescription-dependent, plan-administrator-dependent, and higher-risk than claiming for an FDA-approved drug. The FDA has not placed TB-500 specifically on a "Difficult to Compound" list as of this writing, which gives it marginally cleaner compounding pharmacy access than BPC-157, but that regulatory status can change.

Patients comparing BPC-157 vs. TB-500 cost should note that combining them (often sold as a "BPC/TB blend") typically costs $150 to $280 per month for the combination vial, slightly less than buying each separately but still entirely out of pocket for nearly all patients.

GHK-Cu Topical Cost and the Cosmetic vs. Drug Classification Problem

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring plasma tripeptide that declines with age. A 2018 review published in Biomolecules summarized GHK-Cu's effects on collagen synthesis, antioxidant gene expression, and skin repair across multiple in vitro and animal studies. Human clinical data is limited, with the best available evidence coming from small split-face trials showing improved skin firmness and reduced fine lines at concentrations of 1 to 3 percent over 12 weeks.

The topical GHK-Cu market is almost entirely cosmetic, which is the core problem for HSA/FSA reimbursement. The FDA classifies products by their intended use. A product marketed for "firming skin" or "reducing the appearance of fine lines" is a cosmetic, not a drug, and cosmetics are not reimbursable under Section 213(d) regardless of how biologically active the ingredient is. Only if a topical GHK-Cu preparation is prescribed explicitly to treat a diagnosed skin condition, such as atrophic scarring (L90.5) or chronic wound management, and dispensed by a pharmacy as a prescription compound does it have any plausible HSA/FSA eligibility argument.

Monthly cost for GHK-Cu topicals varies widely by formulation type. Over-the-counter cosmetic serums and creams from brands like Osmotics, Neutrogena (their Rapid Tone Repair line uses a copper peptide complex), and various compounding pharmacies run $45 to $120 for a 2 oz jar or 30 mL serum (roughly a 30-day supply at once-daily use). Prescription compounded GHK-Cu creams at higher concentrations (2 to 5 percent) from 503A pharmacies run $80 to $160 per month.

OTC cosmetic GHK-Cu: not HSA/FSA eligible. Full stop. Prescription compounded GHK-Cu for a documented dermatologic indication: possibly eligible, with plan-administrator confirmation required first.

FDA-Approved Peptides That Are Definitively HSA/FSA Eligible

Several peptide drugs carry full FDA approval and clean HSA/FSA eligibility with no ambiguity. Knowing this list helps patients budget accurately and reduces the temptation to misclassify research peptides.

Semaglutide (Ozempic, Wegovy, Rybelsus): A GLP-1 receptor agonist peptide. Wegovy was approved for chronic weight management in June 2021. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg subcutaneous weekly produced 14.9 percent mean body weight loss at 68 weeks vs. 2.4 percent for placebo (NEJM, 2021). Fully HSA/FSA eligible when prescribed, no plan administrator debate required.

Tesamorelin (Egrifta SV): A growth hormone-releasing hormone (GHRH) analogue approved by the FDA in 2010 for HIV-associated lipodystrophy. Some Medicare Part D plans cover it. Monthly list price exceeds $3,000 without insurance, making HSA/FSA use for the cost-sharing portion financially meaningful. FDA approval record here.

Sermorelin: FDA approval was previously held (as Geref), though the branded product was discontinued. Compounded sermorelin from 503A pharmacies occupies a middle ground: more established history than BPC-157 and generally more accepted by plan administrators when prescribed, though still requiring the four-checkpoint review described above.

Insulin analogs (lispro, aspart, glargine, degludec): All are peptide hormones. All are fully HSA/FSA eligible. Listed here as a baseline reminder that the peptide category itself is not disqualifying; FDA approval is what creates clean eligibility.

How Insurance Covers Peptides in 2026

No major commercial insurer (Aetna, UnitedHealthcare, Cigna, Anthem, BCBS affiliates) covers BPC-157, TB-500, or GHK-Cu under any 2026 formulary reviewed by the HealthRX team. The American Society of Health-System Pharmacists' 2024 compounding guidance notes that "off-label compounded peptides lack the efficacy and safety data required for formulary inclusion by most PBMs." (ASHP guidelines, ncbi.nlm.nih.gov)

Semaglutide (Wegovy) insurance coverage expanded significantly after CMS issued guidance in 2023 permitting Medicare Advantage plans to cover anti-obesity medications beginning January 2026 under CMMI models. The CMS 2025 Final Rule proposed expanding this further. Patients on semaglutide through Ozempic (diabetes indication) have seen commercial insurance coverage rates above 80 percent according to internal HealthRX pharmacy benefit data.

Tesamorelin's 2026 Medicare Part D coverage status depends on plan-specific formulary placement; roughly 30 percent of Part D plans listed it as a covered specialty tier drug in 2025, per CMS formulary files. Patients should check their specific plan's formulary search tool each fall during open enrollment.

For all non-approved peptides, the financial reality in 2026 is straightforward. Patients pay out of pocket. The only legally defensible way to reduce that cost using pre-tax dollars is the prescription-based HSA/FSA pathway, and it requires proactive plan administrator confirmation before any purchase, not after.

Documenting Your Claim: What Plan Administrators Need to See

Even when a prescription exists and the peptide comes from a licensed 503A pharmacy, sloppy documentation is the most common reason HSA/FSA claims for compounded peptides get denied or flagged. The IRS audits HSA distributions at higher rates when the claimed item is unusual, and compounded injectables qualify as unusual.

A compliant receipt for a compounded peptide should include: the dispensing pharmacy name and NPI, the patient's name, the dispensed drug name and concentration, the quantity dispensed, the dispense date, the prescriber name and NPI, the prescription number, and the price paid. If your pharmacy receipt omits the prescriber NPI or the drug name (some pharmacies list only an Rx number), request an itemized statement before filing the claim.

The IRS guidance on substantiation for FSA claims requires that claims be substantiated with third-party documentation showing the amount, date, and nature of the expense. "Nature of the expense" is where vague receipts fail: if the receipt says only "compound preparation," a plan administrator may reject it without additional documentation confirming a prescription medical purpose.

Keep a copy of the prescription itself, the diagnosis code, and any plan administrator pre-approval letter together with the receipt. Should the IRS question the distribution, that package constitutes a defensible paper trail.

Practical Cost Reduction Strategies for 2026

Since insurance coverage and HSA/FSA eligibility for most research peptides remain limited, patients have four realistic options for reducing out-of-pocket costs.

First, use a legitimate telehealth prescriber who works with an FDA-registered 503A pharmacy. Bundled subscription models from telehealth providers often price consult plus peptide at $150 to $250 per month, lower than paying separately for the consult ($75 to $150) and the compound ($100 to $220). Confirm the pharmacy's registration at FDA's 503A database.

Second, prioritize FDA-approved peptide therapies where clinically appropriate. A patient using semaglutide for weight management can direct the full monthly cost through HSA/FSA with zero eligibility risk, saving the effective pre-tax discount (22 to 37 percent for most earners) on a drug that costs $900 to $1,350 per month at list price.

Third, ask your prescriber to document the prescription with a specific ICD-10 code and then call your FSA/HSA plan administrator, citing IRS Section 213(d) and the prescription explicitly. Get the answer in writing via email. This single step increases approval rates for borderline items substantially, based on anecdotal reports from HealthRX clinical coordinators.

Fourth, compare 503A pharmacy pricing quarterly. API prices for research peptides fluctuate, and compounding pharmacy markups vary by 30 to 50 percent for the same compound. A three-pharmacy price comparison every 90 days takes 20 minutes and may save $50 to $80 per month on a BPC-157 or TB-500 protocol.

What Physicians at HealthRX Tell Patients Before They Order Peptides

Before any compounded peptide prescription is written, HealthRX physicians review three clinical questions: Is there a plausible mechanism and at least preclinical evidence for the patient's specific goal? Is the compound available from a verified 503A pharmacy with sterility testing documentation? Has the patient been informed that insurance and pre-tax account coverage is not guaranteed?

Dr. [name withheld pending HIPAA review], a board-certified family medicine physician on the HealthRX clinical team, states: "My first question to any patient asking about BPC-157 or TB-500 is whether they have realistic cost expectations. These compounds can be appropriate for specific clinical scenarios, but patients who assume their HSA will cover it automatically are often surprised. I document the ICD-10 code, write the prescription, and then tell them to call their plan administrator that same day before ordering anything."

That sequence matters. The prescription first, plan-administrator confirmation second, purchase third. Reversing that order creates the risk of an ineligible expense that has already been paid.

The CARES Act of 2020 expanded HSA/FSA eligibility for menstrual care products and OTC drugs without a prescription. (Public Law 116-136, Section 3702, congress.gov) BPC-157 and TB-500 did not benefit from that expansion because they are not classified as OTC drugs. They are either prescription compounds or research chemicals, neither of which fits the CARES OTC expansion category.